BioV8 Life Sciences provides strategic regulatory affairs support across the pharmaceutical and biotechnology product lifecycle—from early development planning through approval and post-marketing activities. Our expertise includes US FDA regulatory strategy, IND, NDA and BLA submissions, health authority meeting preparation, clinical and pediatric regulatory planning, regulatory intelligence, labeling, lifecycle management, and product due diligence. We combine scientific understanding with practical regulatory experience to identify risks, interpret evolving agency expectations, and develop clear, defensible pathways forward. BioV8 provides real world experience delivering focused, senior-level guidance tailored to your product, development stage, and business objectives.
Our Expertise
Pre-Clinical Phase
BioV8 helps sponsors establish a clear regulatory strategy during the preclinical stage by aligning nonclinical studies, CMC development, and the proposed clinical plan with FDA expectations. We identify potential gaps in pharmacology, toxicology, safety margins, and product characterization that could delay IND readiness. Our support includes regulatory pathway assessment, pre-IND planning, study-sequencing recommendations, and development of a risk-based roadmap.
Clinical Phase
BioV8 provides strategic regulatory guidance across Phases I–III, helping sponsors align study design, endpoints, safety monitoring, and evidence-generation plans with FDA expectations. We support protocol and briefing-package development, health authority interactions, pediatric and expedited-program strategies, and resolution of emerging clinical or regulatory risks. By integrating clinical, nonclinical, CMC, and regulatory considerations, BioV8 helps maintain development momentum.
Pre-NDA/BLA and Application Review Phase
BioV8 provides strategic support during pre-NDA/BLA planning and FDA review by assessing submission readiness, identifying content gaps, and aligning clinical, nonclinical, CMC, labeling, and risk-management components. We help sponsors prepare for pre-submission meetings, develop clear regulatory positions, and co-ordinate timely responses to information requests, discipline review letters, and emerging agency concerns. This integrated approach helps reduce review-cycle risk and maintain consistency across the application.
Regulatory Strategy
BioV8 provides practical, integrated regulatory guidance across multiple therapeutic areas and product types, from early development through approval, commercialization, and lifecycle management.
- Alignment of clinical objectives, CMC readiness, and health authority expectations.
- Assessment of expedited development and review pathways.
- Support for labeling, launch readiness, market entry, and lifecycle growth.
Scientific Rigor
BioV8 builds regulatory strategy around the science of each asset—not a one-size-fits-all template. We consider the molecule’s mechanism of action, risk profile and intended use to shape a practical, regulator-ready path.
- Strategy tailored to small molecules, biologics, advanced therapies, and combination products.
- Alignment of study design, evidence generation, and product characterization.
- Early identification of scientific and regulatory gaps.
Quality by Design
BioV8 uses Quality by Design to build quality into the product and process from the start. By linking product characteristics, manufacturing controls, clinical performance, and patient needs, we help create a stronger and more reliable development foundation.
- Define target product profiles and critical quality attributes.
- Identify critical process parameters and aningful performance measures.
- Apply risk-based thinking to guide development decisions.
Contact
Start the conversation
Tell us about your program and we'll get back to you shortly.